SCM
ENTA icon

Sarissa Capital Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Sarissa Capital Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-105,000
Closed -$4.16M – 17
2014
Q3 		$4.16M Hold
105,000
– – 1.6% 10
2014
Q2 		$4.52M Buy
105,000
+55,000
+110% +$2.1M 1.54% 10
2014
Q1 		$2M Buy
+50,000
New +$1.82M 0.69% 13

Other funds holding ENTA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
ACM
Apex Capital Management Dayton, Ohio $4.54B AUM 1.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Sarissa Capital Management's ENTA Position: Q4 2014 in Review

Sarissa Capital Management sold out of Enanta Pharmaceuticals (ENTA) in Q4 2014, closing a stake of 105,000 shares — an estimated $4.16M sold.

Sarissa Capital Management first reported a position in ENTA in Q1 2014 and held it in 3 quarters. The position peaked at $4.52M in Q2 2014. 125 funds tracked by Wall St. Rank hold ENTA as of Q4 2014.

  • Sarissa Capital Management reported no remaining Enanta Pharmaceuticals position as of Q4 2014 after selling out during the quarter.
  • Sarissa Capital Management sold 105,000 Enanta Pharmaceuticals shares in Q4 2014, an estimated $4.16M.
  • Sarissa Capital Management first reported a position in Enanta Pharmaceuticals in Q1 2014 and held it in 3 quarters.
  • Sarissa Capital Management's Enanta Pharmaceuticals position peaked at $4.52M in Q2 2014.
  • 125 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2014.

Based on Sarissa Capital Management's 13F filing for Q4 2014, filed 17 Feb 2015.